Related Experiment Videos
Imiquimod therapy for molluscum contagiosum
E Liota1, K J Smith, R Buckley
1Department of Dermatology, National Naval Medical Center, Bethesda, Maryland 20089-5600, USA.
Journal of Cutaneous Medicine and Surgery
|February 17, 2001
Summary
Topical imiquimod cream shows efficacy in treating molluscum contagiosum virus (MCV) lesions, particularly in HIV-1 patients and adults. While effective, children experienced more side effects like pruritus, impacting overall lesion resolution.
Area of Science:
- Dermatology
- Virology
- Immunology
Background:
- Molluscum contagiosum virus (MCV) is a widespread double-stranded DNA poxvirus.
- MCV evades immune detection via virus-specific proteins, without establishing latency.
Purpose of the Study:
- To assess the therapeutic effectiveness of imiquimod 5% cream for molluscum contagiosum virus infections.
Main Methods:
- A study involving 13 children (5-10 years), 19 immunocompetent adults, and 4 HIV-1 positive adults with MCV lesions.
- Participants received topical 5% imiquimod cream three times weekly for up to 16 weeks.
Main Results:
- Resolution of MCV lesions was observed in 14/19 immunocompetent adults, 4/4 HIV-1 patients, and 6/13 children within 16 weeks.
- Children reported increased pruritus and inflammation; new lesion development lowered resolution rates in this group.
- Imiquimod demonstrated highest efficacy in HIV-1 patients and on genital areas in immunocompetent adults.
Conclusions:
- Topical imiquimod exhibits therapeutic potential for MCV, with better response in adults, especially in areas with enhanced penetration.
- Pruritus in children correlated with new lesion development, suggesting a need for tailored treatment approaches.
- HIV-1 positive patients, despite larger initial lesions, showed the most favorable overall response to imiquimod therapy.